Is this your business? Claim it to manage your IP and profile
The xT CDx is a sophisticated tumor profiling assay, FDA-approved, designed to serve as a comprehensive genomic testing tool for patients with solid tumor malignancies. It utilizes a 648-gene panel optimized for DNA sequencing, capturing single nucleotide variants, multi-nucleotide variants, and insertion-deletion alterations. This sequence data, derived from FFPE tumor tissues and matched normal specimens, affords highly reliable insight into tumor genetics, significantly aiding therapeutic decisions. Beyond standard profiling, xT CDx is intended as a companion diagnostic to pinpoint patients likely to benefit from targeted therapies. Its precise mutation profiling offers healthcare professionals a robust framework for making informed decisions in line with established oncology guidelines. The assay distinguishes itself by integrating normal and tumor DNA analysis, enhancing the accuracy of somatic alteration identification by reducing false positive results. This functionality extends valuable data that clinical professionals can seamlessly incorporate into bespoke cancer care strategies, maximizing therapeutic efficacy.
The xF+ Liquid Biopsy Panel is an innovative genomic testing solution that focuses on circulating tumor DNA to provide an expansive view of tumor genetics. By examining 105 to 523 genes, this panel aids in the detection of genetic variants actionable in therapeutic contexts, including the determination of MSI-H status and blood-based tumor mutational burden. Characteristically, the panel is engineered to maximize the detection of discrete genetic alterations in the bloodstream, which are often elusive in traditional solid tumor samplings. Suitable for patients with various solid tumors, it enables the identification of unique actionable variants that could otherwise be missed. This comprehensive approach through xF+ provides invaluable information related to tumor progression and therapeutic resistance. As it captures data directly from the bloodstream, it is a minimally invasive option that offers recurrent monitoring capabilities to guide ongoing therapeutic regimens.
The DPYD Test by Tempus is an essential pharmacogenomic tool designed to identify patients at risk of severe toxicity from 5-FU and capecitabine treatments. Targeting the DPYD gene, this test screens for specific SNVs that can predict adverse drug reactions, thereby playing a crucial role in personalizing chemotherapy treatments. DPYD testing is particularly critical for patients receiving treatments for colorectal, breast, pancreatic, and other gastro-intestinal cancers. By analyzing the metabolic pathways and genetic makeup, the test forewarns clinicians of potential overreaction to standard chemotherapeutic drugs, helping in optimizing therapeutic protocols. This test's ability to provide deep insights into patient-specific drug metabolism supports oncologists in refining treatment plans, minimizing side effects, and enhancing therapeutic efficacy. As such, its use in precision oncology supports the development of patient-centered care regimens that prioritize safety and efficacy.
The Tempus xT CDx is a specialized genomic test, FDA-sanctioned, designed to provide deep insights into the genetic landscape of solid tumors. It encompasses a broad spectrum of 648 genes and is crafted to identify pertinent genomic alterations that could guide therapeutic decisions. This test employs both tumor and matched normal DNA, ensuring that somatic mutations are precisely identified with heightened accuracy. The assay is integral to the precision medicine initiative, assisting in the determination of targeted therapies that patients are likely to respond to. Additionally, it provides comprehensive tumor mutation profiling to assist healthcare professionals in adhering to oncological guidelines when deciding on treatment plans. Through comprehensive gene sequencing, Tempus xT CDx reveals specific genetic mutations and MSI status, refining clinical decision-making by mapping out individualized treatment pathways. Its targeted approach significantly optimizes treatment plans for cancer patients by ensuring that therapeutic interventions are as personalized and effective as possible.
Intel expands its foundry ecosystem with alliances with TSMC, UMC, and Taiwanese tech partners, marking a major transformation for the firm's production strategy. Read more
Join the world's most advanced semiconductor IP marketplace!
It's free, and you'll get all the tools you need to discover IP, meet vendors and manage your IP workflow!
No credit card or payment details required.
Join the world's most advanced AI-powered semiconductor IP marketplace!
It's free, and you'll get all the tools you need to advertise and discover semiconductor IP, keep up-to-date with the latest semiconductor news and more!
Plus we'll send you our free weekly report on the semiconductor industry and the latest IP launches!
To evaluate IP you need to be logged into a buyer profile. Select a profile below, or create a new buyer profile for your company.
